Chondrogen + Chondrogen + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recovery Following Partial Medial Meniscectomy
Conditions
Recovery Following Partial Medial Meniscectomy
Trial Timeline
Jun 1, 2008 → Sep 1, 2011
NCT ID
NCT00702741About Chondrogen + Chondrogen + Placebo
Chondrogen + Chondrogen + Placebo is a phase 1/2 stage product being developed by Mesoblast for Recovery Following Partial Medial Meniscectomy. The current trial status is completed. This product is registered under clinical trial identifier NCT00702741. Target conditions include Recovery Following Partial Medial Meniscectomy.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00702741 | Phase 1/2 | Completed |
Competing Products
3 competing products in Recovery Following Partial Medial Meniscectomy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BAY207543 (Bepanthol, Bepantol® Derma Spray) | Bayer | Approved | 82 |
| BAY207543 (Bepanthol, Bepantol® Derma Spray) | Bayer | Approved | 82 |
| Mesenchymal Stem Cells + Hyaluronan | Mesoblast | Phase 1/2 | 36 |